Recherches "plusieurs pathologies" RAGNAR (42756493CAN2002) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene;Alterations Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
VADS SKYSCRAPER-09 (BO42533) A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique HER2+ BO25430 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY. Saint-Cloud FLORENCE LEREBOURS
VADS BGB-HNSCC-201 A Randomized, Phase 2, Open-Label, Multi-Arm;Study of Tislelizumab in Combination With;Investigational Agents as First-Line Treatment in;Patients With Recurrent or Metastatic Head and Neck;Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
VADS 219885 219885 GALAXIES H&N-202 A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck Paris CHRISTOPHE LE TOURNEAU